Chimeric Therapeutics Limited (CHMMF)
Chimeric Therapeutics Limited
62 Lygon Street
Level 3 Carlton South
Carlton, VIC 3053
Australia
61 3 9824 5254
https://www.chimerictherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Founder & Executive Chairman | 166.51k | N/D | 1956 |
| Mr. Eliot Bourk | Chief Business Officer & Head of External Innovation | 556.92k | N/D | N/D |
| Mr. Jason B. Litten M.D. | Chief Medical Officer | 681.11k | N/D | 1974 |
| Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. | CFO, Joint Company Secretary & Director | N/D | N/D | 1959 |
| Dr. Rebecca McQualter | Chief Operating Officer | N/D | N/D | N/D |
| Mr. Kelly R. Thornburg | VP & Head of Quality | N/D | N/D | 1963 |
| Mr. Nathan Jong C.A. | Company Secretary | N/D | N/D | N/D |
Descripción
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.
Gestión corporativa
La calificación ISS Governance QuickScore de Chimeric Therapeutics Limited a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
